No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating, recommending investors to build positions at a "compelling entry point".
The bank hailed AstraZeneca as an "innovation leader", saying that the company has an underappreciated pipeline with exposure to high-value markets across oncology, cardiovascular/renal and next-generation immuno-oncology.
"With pivotal clinical data starting in 2025+, success across these markets, could start to unlock value closer to our bull case valuation, 160/share," Morgan Stanley said. That compares with Tuesday's closing price of 11,624p.
As for the near term, 2025 should be a "catalyst-rich year", delivering double-digit bottom-line growth alongside continued strong product sales momentum, the bank said.
On Morgan Stanley's estimates, the stock trades at 15 times estimated earnings for 2025. While this is a 30% premium to other large-cap pharma peers, it is "justifiable given the superior top-line driven growth outlook [...] and significantly greater pipeline optionality," the bank said.
For now, Morgan Stanley has set a 14,500p target price for the shares, which were down 0.2% at 11,606p by 1054 GMT.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.